But curiously enough, adjuvant endocrine therapy including tamoxifen and aromatase inhibitors brought about a definite and highly significant decrease in the incidence of contralateral breast cancer for women with estrogen receptor (ER)-positive or ER-unknown disease [2], [29]–[31]. This evidence concerns the gene ESR1 and breast carcinoma.